Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Volume of distribution of a drug is given by?

Vd = Dose administered i.v. / Plasma concentration. **Explanation:** **1. Why Option A is Correct:** The **Apparent Volume of Distribution (Vd)** is a theoretical volume that relates the total amount of drug in the body to the concentration of the drug measured in the plasma. It is calculated using the formula: **Vd = Total amount of drug in the body (Dose) / Plasma concentration (C)** When a drug is administered intravenously (i.v.), the entire dose enters the systemic circulation immediately. Therefore, Vd represents the space required to contain the drug if it were distributed homogeneously at the same concentration found in the plasma. **2. Why Other Options are Incorrect:** * **Option B:** This describes a ratio related to the Therapeutic Index or safety margin, not distribution. * **Option C:** While lipid solubility *influences* Vd (high lipid solubility usually leads to a high Vd), it is not a mathematical component of the formula. * **Option D:** This is a distractor. While Vd is used to calculate half-life ($t_{1/2} = 0.693 \times Vd / CL$), the formula provided is mathematically incorrect. **3. NEET-PG High-Yield Clinical Pearls:** * **Loading Dose:** Vd is the primary determinant of the loading dose ($LD = Vd \times Target\ Plasma\ Concentration$). * **Low Vd ( 40L):** Indicates the drug is sequestered in peripheral tissues/fat (e.g., **Chloroquine, Digoxin**). * **Dialysis:** Drugs with a high Vd cannot be efficiently removed by hemodialysis because most of the drug is outside the plasma. * **Plasma Protein Binding:** Drugs with high plasma protein binding tend to have lower Vd.

Q: Which of the following drugs has the maximum chance of absorption from the gastric mucosa?

Diclofenac sodium. ### Explanation The absorption of a drug across biological membranes is primarily governed by its **degree of ionization**, which depends on the drug's pKa and the pH of the surrounding medium. According to the **pH Partition Hypothesis**, only the non-ionized (lipid-soluble) form of a drug can easily cross lipid membranes. **1. Why Diclofenac Sodium is Correct:** Diclofenac is a **weakly acidic drug** (pKa ≈ 4.0). In the highly acidic environment of the stomach (pH 1–2), weak acids remain largely in their **non-ionized, protonated form**. This makes them lipid-soluble and allows for significant absorption directly through the gastric mucosa. **2. Why the Other Options are Incorrect:** * **Morphine sulfate, Hyoscine hydrobromide, and Quinine dihydrochloride** are all **weakly basic drugs**. * In the acidic gastric environment, basic drugs become **highly ionized** (protonated). * Ionized molecules are water-soluble but lipid-insoluble; therefore, they cannot cross the gastric mucosal barrier effectively. These drugs are primarily absorbed later in the alkaline environment of the small intestine. **3. High-Yield Clinical Pearls for NEET-PG:** * **General Rule:** Acidic drugs (e.g., Aspirin, Barbiturates, NSAIDs like Diclofenac) are absorbed better in acidic media (stomach). Basic drugs (e.g., Atropine, Morphine, Amphetamines) are absorbed better in alkaline media (intestine). * **Surface Area Factor:** Despite the chemistry, the **small intestine** remains the major site of absorption for *most* drugs (including weak acids) due to its massive surface area compared to the stomach. * **Ion Trapping:** This principle is used clinically in toxicology. For example, alkalinizing the urine with sodium bicarbonate "traps" acidic drugs like Aspirin in the renal tubules, enhancing their excretion.

Q: Which of the following is FALSE regarding non-competitive antagonism?

The drug needs to be structurally similar to the substrate.. ### Explanation In pharmacology, understanding the distinction between competitive and non-competitive antagonism is high-yield for NEET-PG. **Why Option B is the Correct (False) Statement:** In **non-competitive inhibition**, the antagonist does not compete for the same binding site as the substrate. Instead, it binds to an **allosteric site** (a different location on the enzyme or receptor). Because it does not target the active site, the antagonist **does not need to be structurally similar** to the substrate. Structural similarity is a hallmark of *competitive* inhibition, where the drug "mimics" the substrate to fit into the active site. **Analysis of Other Options:** * **Option A (True):** Non-competitive inhibitors bind to allosteric sites, inducing a conformational change in the enzyme that reduces its catalytic activity. * **Option C (True):** Since the inhibitor and substrate are not competing for the same spot, adding more substrate cannot "wash out" or displace the inhibitor. Therefore, the inhibition is **insurmountable**, and the **Vmax is decreased**. * **Option D (True):** In non-competitive inhibition, the affinity of the remaining functional enzymes for the substrate typically remains unchanged. Therefore, the **Km (Michaelis constant) remains the same**. **High-Yield Clinical Pearls for NEET-PG:** * **Competitive Inhibition:** Km increases, Vmax remains unchanged (e.g., Statins vs. HMG-CoA). * **Non-Competitive Inhibition:** Km remains unchanged, Vmax decreases (e.g., Digoxin acting on Na+/K+ ATPase). * **Irreversible Inhibition:** Often grouped with non-competitive kinetics because Vmax decreases (e.g., Aspirin inhibiting COX, Organophosphates inhibiting AChE). * **Key Graph:** On a Lineweaver-Burk plot, non-competitive inhibitors show lines that intersect on the negative X-axis (same -1/Km).

Q: Dosage of a drug is determined by all of the following factors except?

Half-life. To determine the correct dosage of a drug, we must distinguish between the **Loading Dose** and the **Maintenance Dose**. **Why Half-life is the correct answer:** The **half-life ($t_{1/2}$)** of a drug determines the **dosing interval** (how often the drug is given) and the time required to reach **steady-state concentration**, but it does not directly determine the *amount* (dosage) of the drug itself. Dosage is primarily calculated based on Clearance and Volume of Distribution. **Explanation of Incorrect Options:** * **Volume of Distribution ($V_d$):** This is the primary determinant of the **Loading Dose**. Drugs with a high $V_d$ sequester into tissues, requiring a larger initial dose to achieve the desired target plasma concentration ($LD = V_d \times C_p$). * **Excretion/Clearance:** The rate of drug elimination (Clearance) is the primary determinant of the **Maintenance Dose**. If excretion is impaired (e.g., renal failure), the dose must be reduced to avoid toxicity ($MD = CL \times C_{ss}$). * **Lipid Solubility:** This physicochemical property dictates the $V_d$. Highly lipid-soluble drugs cross biological membranes easily and distribute widely into adipose tissue, necessitating dosage adjustments based on body composition. **NEET-PG High-Yield Pearls:** 1. **Loading Dose** depends on **$V_d$** (Targeting the "tank" size). 2. **Maintenance Dose** depends on **Clearance** (Targeting the "leak" rate). 3. **Steady State** is reached after **4–5 half-lives**, regardless of the dose or frequency, provided the infusion/dosing is constant. 4. **Bioavailability (F):** Must be considered for oral dosing ($LD = \frac{V_d \times C_p}{F}$).

Q: Which of the following are examples of physiological antagonism?

Both B and C. ### Explanation **Concept of Physiological Antagonism** Physiological (or functional) antagonism occurs when two drugs act on **different receptors** and produce **opposing physiological effects** on the same effector organ or system. Unlike pharmacological antagonism, they do not compete for the same receptor site. **Why Option D (Both B and C) is Correct:** * **Adrenaline and Histamine (Option B):** This is the classic textbook example. Histamine acts on **H₁ receptors** causing bronchoconstriction and vasodilation. Adrenaline acts on **β₂ receptors** (bronchodilation) and **α₁ receptors** (vasoconstriction). Because they produce opposite effects via different receptors, adrenaline is the physiological antagonist of histamine and is the drug of choice for anaphylactic shock. * **Salbutamol and Leukotrienes (Option C):** Leukotrienes (e.g., LTC4, LTD4) act on **CysLT₁ receptors** to cause potent bronchoconstriction. Salbutamol acts on **β₂ receptors** to cause bronchodilation. Since they act on different receptors to produce opposite effects on bronchial smooth muscle, they are physiological antagonists. **Why Option A is Incorrect:** * **Adrenaline and Salbutamol:** Both drugs are **agonists** at the β₂-adrenergic receptor. They produce synergistic (additive) effects on bronchodilation rather than opposing each other. **NEET-PG High-Yield Pearls:** * **Chemical Antagonism:** Occurs when two drugs react chemically in solution (e.g., Heparin and Protamine sulfate; Chelating agents and heavy metals). * **Pharmacological Antagonism:** Occurs at the same receptor (e.g., Atropine and Acetylcholine at Muscarinic receptors). * **Clinical Application:** Adrenaline is used in anaphylaxis because it works instantly via physiological antagonism, bypassing the histamine receptor blockade which would be too slow.

Q: In competitive antagonism, what happens to the Vmax?

Vmax remains the same. In **competitive antagonism**, the antagonist binds reversibly to the same active site as the agonist. Because they compete for the same receptor, the outcome depends on the relative concentrations of the two molecules. ### Why the correct answer is right: * **Vmax (Efficacy) remains the same:** If you increase the concentration of the agonist sufficiently, it can "outcompete" and displace the antagonist from the receptors. Therefore, the maximal response (Vmax or Emax) can still be achieved, provided enough agonist is present. On a graph, this is represented by a **parallel rightward shift** of the dose-response curve. ### Why the incorrect options are wrong: * **Potency remains the same:** This is incorrect. Because more agonist is required to achieve the same effect in the presence of an antagonist, the **EC50 increases**, meaning the **potency decreases**. * **Km decreases:** In enzyme kinetics (analogous to receptor binding), competitive inhibition **increases the Km** (Michaelis constant). A higher Km indicates a decreased affinity of the enzyme/receptor for the substrate/agonist. * **Efficacy decreases:** This is a characteristic of **non-competitive antagonism**, where the antagonist binds to an allosteric site or binds irreversibly, preventing the agonist from reaching Vmax regardless of the dose. ### High-Yield Clinical Pearls for NEET-PG: * **Competitive Antagonism:** Parallel rightward shift, Vmax constant, Km/EC50 increases. (Example: Atropine vs. Acetylcholine). * **Non-Competitive Antagonism:** Downward shift, Vmax decreases, Km/EC50 remains constant. (Example: Phenoxybenzamine at alpha receptors). * **Key Distinction:** Competitive antagonism can be overcome by increasing agonist concentration; non-competitive cannot.

Q: Which route of administration will produce the least onset of action?

Application to a bronchotracheal mucous membrane. ### Explanation The speed of onset of action for any drug is primarily determined by the **vascularity** of the site of administration and the **surface area** available for absorption. **Why Option C is Correct:** The **bronchotracheal mucous membrane** has a relatively smaller surface area and lower vascular density compared to the alveolar surface or direct intravenous access. While absorption through mucous membranes is generally faster than the oral route, it is significantly slower than the other options provided. Therefore, among the choices, it produces the **least (slowest) onset of action.** **Analysis of Incorrect Options:** * **D. Injection into blood vessels (Intravenous):** This provides the **fastest** onset of action because it bypasses the absorption phase entirely, achieving immediate 100% bioavailability. * **B. Inhalation of gaseous form:** This involves the **alveolar membrane**, which has a massive surface area (approx. 70-100 $m^2$) and an extremely rich capillary network. This results in an onset of action almost as rapid as an IV injection (e.g., volatile anesthetics). * **A. Application to a serous surface:** Serous membranes (like the peritoneum) have a very large surface area and high vascularity, leading to very rapid absorption, often faster than mucous membrane application. **NEET-PG High-Yield Pearls:** * **Order of Onset Speed:** IV > Inhalation (Alveolar) > Intraperitoneal/Serous > Intramuscular > Subcutaneous > Oral. * **Bioavailability:** Defined as the fraction of an unchanged drug that reaches the systemic circulation. It is 100% (1.0) for the IV route. * **First-Pass Metabolism:** Routes that bypass the liver (IV, Sublingual, Transdermal, Inhalation) have higher systemic availability compared to the oral route.

Question 1

What is the plasma half-life of aspirin?

Accepted Answer

Longer for anti-inflammatory doses compared to analgesic doses

Answer

Independent of dose

Answer

Shorter for anti-inflammatory doses compared to analgesic doses

Answer

Can be increased by alkalinizing the urine

Question 2

A patient is prescribed propranolol with the following pharmacokinetic parameters: Volume of Distribution (Vd) = 300 L/70 kg, Clearance (C1) = 700 mL/min, and oral bioavailability (f) = 0.25. What is the oral dose required to achieve a plasma concentration of 20 mg/L?

Accepted Answer

24 mg

Answer

4 mg

Answer

12 mg

Answer

48 mg

Question 3

Volume of distribution of a drug is given by?

Accepted Answer

Vd = Dose administered i.v. / Plasma concentration

Answer

Vd = Maximum tolerated dose / Dose administered i.v.

Answer

Vd = Dose administered i.v. / Total lipid solubility

Answer

Vd = t 1/2 / Dose administered i.v.

Question 4

Which of the following drugs has the maximum chance of absorption from the gastric mucosa?

Accepted Answer

Diclofenac sodium

Answer

Morphine sulfate

Answer

Hyoscine hydrobromide

Answer

Quinine dihydrochloride

Question 5

Which of the following is FALSE regarding non-competitive antagonism?

Accepted Answer

The drug needs to be structurally similar to the substrate.

Answer

The drug binds to an allosteric site of the enzyme.

Answer

The inhibition cannot be overcome by increasing the substrate concentration.

Answer

The Km remains the same.

Question 6

Dosage of a drug is determined by all of the following factors except?

Accepted Answer

Half-life

Answer

Volume of distribution

Answer

Lipid solubility

Answer

Excretion of the drug

Question 7

Which of the following are examples of physiological antagonism?

Accepted Answer

Both B and C

Answer

Adrenaline and salbutamol

Answer

Adrenaline and histamine

Answer

Salbutamol and leukotrienes

Question 8

In competitive antagonism, what happens to the Vmax?

Accepted Answer

Vmax remains the same

Answer

Potency remains the same

Answer

Km decreases

Answer

Efficacy decreases

Question 9

Which route of administration will produce the least onset of action?

Accepted Answer

Application to a bronchotracheal mucous membrane

Answer

Application to a serous surface

Answer

Inhalation of gaseous form

Answer

Injection into blood vessels

Question 10

Receptor agonists possess which of the following properties?

Accepted Answer

Affinity and intrinsic activity

Answer

Affinity but no intrinsic activity

Answer

Intrinsic activity but no affinity

Answer

Affinity and intrinsic activity with a negative effect

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?